SEARCH

SEARCH BY CITATION

Keywords:

  • Gleason grade;
  • prostate carcinoma;
  • radical prostatectomy

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References

What's known on the subject? and What does the study add?

  • The Gleason scoring system is a well-established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades – most recently by the International Society of Urological Pathology (ISUP) in 2005 – have attempted to improve the correlation between biopsy and radical prostatectomy Gleason sum and better stratify patients to predict clinical outcomes.
  • Based on these clinical outcomes and the excellent prognosis for patients with low Gleason scores, we recommend Gleason grades incorporating a prognostic grade grouping which accurately reflect prognosis and are clearly understood by physicians and patients alike.

Objective

  • To investigate pathological and short-term outcomes since the most recent Gleason system modifications by the International Society of Urological Pathology (ISUP) in an attempt to divide the current Gleason grading system into prognostically accurate Gleason grade groups.

Patients and Methods

  • We queried the Johns Hopkins Radical Prostatectomy Database (1982–2011), approved by the institutional review board, for men undergoing radical prostatectomy (RP) without a tertiary pattern since 2004 and identified 7869 men.
  • Multivariable models were created using preoperative and postoperative variables; prognostic grade group (Gleason grade ≤6; 3 + 4; 4 + 3; 8; 9–10) was among the strongest predictors of biochemical recurrence-free (BFS) survival.

Results

  • Significant differences were noted among the Gleason grade groups at biopsy; differences were noted in the race, PSA level, clinical stage, number of positive cores at biopsy and the maximum percentage of positive cores among the Gleason grade groups at RP.
  • With a median (range) follow-up of 2 (1–7) years, 5-year BFS rates for men with Gleason grade ≤6, 3 + 4, 4 + 3, 8 and 9–10 tumours at biopsy were 94.6, 82.7, 65.1, 63.1 and 34.5%, respectively (P < 0.001 for trend); and 96.6, 88.1, 69.7, 63.7 and 34.5%, respectively (P < 0.001), based on RP pathology.

Conclusions

  • The 2005 ISUP modifications to the Gleason grading system for prostate carcinoma accurately categorize patients by pathological findings and short-term biochemical outcomes but, while retaining the essence of the Gleason system, there is a need for a change in its reporting to more closely reflect tumour behaviour.
  • We propose reporting Gleason grades, including prognostic grade groups which accurately reflect prognosis as follows: Gleason score ≤6 (prognostic grade group I); Gleason score 3+4=7 (prognostic grade group II); Gleason score 4+3=7 (prognostic grade group III); Gleason score 4+4=8 (prognostic grade group (IV); and Gleason score 9–10 (prognostic grade group (V).

Abbreviations
ISUP

International Society of Urological Pathology

RP

radical prostatectomy

PPC

percentage of positive cores

c

concordance

Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References

The Gleason grading system for prostate cancer was developed in the 1960s and remains the strongest predictor of outcome for men diagnosed with prostate carcinoma [1]. The current Gleason grading system has evolved from its original description, first modified by Gleason and Mellinger in 1974 [2] and most recently in 2005 by the International Society of Urological Pathology (ISUP) [3]. With the new modifications, a number of studies indicate that there is better correlation between biopsy and radical prostatectomy (RP) Gleason grade and stage, as well as with biochemical recurrence, than previously [4-8].

These newest modifications when applied to needle biopsies, while demonstrating improved correlation with RP grade, stage, margins, tumour volume and postoperative progression, are also more complicated than previous versions [4-9]. For instance, in the setting of high grade cancer on needle biopsy, if there is also low grade cancer on the same core occupying less than 5% of the cancer, the low grade cancer is not included in the Gleason score. The tertiary highest grade pattern is included in the biopsy score yet not the RP score. In several previous studies, we have shown that tertiary Gleason pattern has a risk of recurrence that lies in between the current grading system gradations; for example, Gleason score 6 with a tertiary higher grade component has a prognosis between Gleason score 6 and Gleason score 3 + 4 = 7 [10]. The purpose of the present study was to investigate the pathological findings and short-term biochemical outcomes of tumours graded since the ISUP Consensus in an attempt to divide the current Gleason grading system into prognostically accurate Gleason grade groups.

Patients and Methods

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References

The institutional-review-board-approved, Johns Hopkins Radical Prostatectomy Database (1982–2011) was queried for men undergoing RP since 2004, which was identified as the time of development and implementation of the most recent grading guidelines. A total of 7869 were identified, of whom 19 men were missing complete biopsy data and were excluded from the analysis of biopsy Gleason score. Pathological analysis of the RP specimen has been described previously [10, 11]. Briefly, specimens were serially sectioned and submitted in entirety and reviewed by general surgical pathologists, with daily consultation of urological pathologists for issues relating to grade, stage and margins. In cases where there are three patterns on a biopsy core (typically Gleason patterns 3, 4 and 5), the Gleason score is derived by adding the most common pattern and the highest pattern as recommended [3]. The following Gleason score groups were considered: ≤6; 3 + 4 = 7; 4 + 3 = 7; 8; and 9–10. In cases with multiple cores with differing Gleason scores, the highest score in a case was selected as the case's grade. In analysis of RP specimens, intermediate categories were created by adding the designation ‘T’ to each existing category when a higher tertiary pattern was present. Gleason score ≤6 could have a tertiary pattern 4 or 5, while T refers to tertiary pattern 5 only for the remaining Gleason score groups. The RP grade assigned was based on the tumour nodule with the highest grade, rather than an overall grade for all of the tumour in the prostate. In a minority of cases, pathological stage was unknown as a result of intraprostatic incision, which accounts for the discrepancy between the number of cases in Tables 1 and 2 compared with Table 3.

Table 1. Baseline patient and prostate cancer characteristics for 7850 patients diagnosed with prostate cancer since the 2005 ISUP modifications to the Gleason system, stratified by biopsy Gleason score.
CharacteristicBiopsy Gleason scoreP
≤63 + 44 + 34 + 49–10
  1. *Gleason 6 tumours had a significantly lower PPC when compared with other groups (P < 0.001), however the P value for the trend was nonsignificant.

All patients, n (%)5205 (66.3)1611 (20.5)639 (8.1)272 (3.5)123 (1.6) 
Median (range) age, years58 (34–79)60 (34–76)61 (41–75)61 (38–74)(40–76)0.323
Family history, n (%)1920 (36.9)581 (36.1)224 (35.1)89 (32.7)43 (35.0)0.075
Race, n (%)     0.4
African–American537 (10.3)199 (12.4)87 (13.6)37 (13.6)16 (13.0) 
Caucasian4383 (84.2)1315 (81.6)509 (79.7)218 (80.1)98 (79.7) 
Other285 (5.5)97 (6.0)43 (6.7)17 (6.3)9 (7.3) 
Median (range) PSA, ng/mL4.7 (0.2–97.2)5.1 (0.1–64.8)5.1 (1.1–43.3)5.8 (0.9–49.9)5.6 (1.2–44)<0.001
Clinical stage, n (%)     <0.001
cT1c3707 (84.3)792 (65.2)281 (62.9)114 (61.0)38 (42.7) 
cT2a597 (13.6)328 (27.0)102 (22.8)48 (25.7)25 (28.1) 
cT2b94 (2.1)88 (7.2)62 (13.9)71 (38.0)21 (23.6) 
cT2c–cT317 (0.4)29 (2.4)10 (2.2)2 (1.1)8 (9.0) 
Mean (range) no. of positive cores2.64 (1–12)4.00 (1–14)4.03 (1–15)4.22 (1–15)4.83 (1–16)<0.001
Median (range) maximum PPC30 (1–100)60 (5–100)60 (3–100)68 (5–100)80 (5–100)0.688*
Table 2. Baseline patient and prostate cancer characteristics for 7869 patients diagnosed with prostate cancer since the 2005 ISUP modifications to the Gleason system, stratified by RP Gleason score.
RP Gleason score≤6≤6 + T3 + 43 + 4 + T4 + 3
All patients, n (%)3548 (45.1)789 (10.0)1972 (25.1)192 (2.4)603 (7.7)
Median (range) age, years58 (34–81)58 (36–75)59 (36–75)59.5 (41–74)61 (38–73)
Family history, n (%)1312 (37.0)310 (39.3)723 (36.7)66 (34.4)205 (34.0)
Race, n (%)     
African–American335 (9.4)86 (10.9)255 (12.9)27 (14.1)76 (12.6)
Caucasian3019 (85.1)669 (84.8)1602 (81.2)152 (79.2)479 (79.4)
Other194 (5.5)34 (4.3)115 (5.8)13 (6.8)48 (8.0)
Median (range) PSA, ng/mL4.5 (0.2–43.1)4.8 (0.5–50)5.1 (0.3–97.2)5.9 (0.9–49.9)5.6 (1.2–62.2)
Clinical stage, n (%)     
cT1c2917 (82.2)626 (79.3)1402 (71.1)139 (72.4)395 (65.5)
cT2a463 (13.0)119 (15.1)382 (19.4)30 (15.6)122 (20.2)
cT2b67 (1.9)23 (2.9)101 (5.1)20 (10.4)61 (10.1)
cT2c–cT310 (0.3)4 (0.5)32 (1.6)0 (0.0)10 (1.7)
Mean (range) no. of positive cores2.48 (1–12)3.42 (1–12)3.61 (1–14)4 (1–13)3.56 (1–15)
Median (range) maximum PPC30 (1–100)50 (2–100)50 (3–100)50 (5–100)60 (5–100)
RP Gleason score4 + 3 + T4 + 44 + 4 + T9 to 10P
All patients, n (%)285 (3.6)142 (1.8)74 (0.9)264 (3.4) 
Median (range) age, years61 (39–77)61 (40–76)59 (45–72)60 (41–75)0.103
Family history, n (%)101 (35.4)49 (34.5)24 (32.4)77 (29.2)0.937
Race, n (%)    0.025
African–American46 (16.1)14 (9.9)11 (14.9)26 (9.8) 
Caucasian226 (79.3)116 (81.7)60 (81.1)217 (82.2) 
Other13 (4.6)12 (8.5)3 (4.1)21 (8.0) 
Median (range) PSA, ng/mL5.8 (1.1–64.8)5.4 (0.9–22.8)6.0 (2.0–43.3)5.8 (0.1–55.0)<0.001
Clinical stage, n (%)    <0.001
cT1c185 (64.9)85 (59.9)44 (59.5)139 (52.7) 
cT2a53 (18.6)36 (25.4)17 (23.0)50 (18.9) 
cT2b31 (10.9)15 (10.6)11 (14.9)46 (17.4) 
cT2c–cT39 (3.2)0 (0.0)1 (1.4)15 (5.7) 
Mean (range) no. of positive cores4.31 (1–15)3.56 (1–10)3.96 (1–14)3.78 (1–16)<0.001
Median (range) maximum PPC60 (5–100)50 (5–100)70 (10–100)70 (1–100)<0.001
Table 3. Distribution of pathological stage at RP stratified by biopsy and RP Gleason score.
Pathological stageOC: pT2EPE: pT3aSVI: pT3bLNI: N1P
  1. OC, organ-confined (pT2); EPE, extraprostatic extension (pT3a); SVI, seminal vesicle invasion (pT3b); LNI, lymph node involvement (N1).

Biopsy Gleason score, n (%)    <0.001
≤64315 (83.0)823 (15.8)49 (0.9)12 (0.2) 
3 + 4967 (60.2)524 (32.6)86 (5.4)29 (1.8) 
4 + 3320 (50.4)234 (36.9)52 (8.2)29 (4.6) 
4 + 4130 (47.8)104 (38.2)25 (9.2)13 (4.8) 
9 to 1043 (35.0)39 (31.7)21 (17.1)20 (16.3) 
RP Gleason score, n (%)    <0.001
≤63218 (90.8)314 (8.9)11 (0.3)2 (0.1) 
≤6 + T600 (76.3)182 (23.2)3 (0.4)1 (0.1) 
3 + 41275 (64.8)625 (31.7)54 (2.7)15 (0.8) 
3 + 4 + T89 (46.8)81 (42.6)18 (9.5)2 (1.1) 
4 + 3303 (50.4)234 (38.9)40 (6.7)24 (4.0) 
4 + 3 + T106 (37.2)130 (45.6)35 (12.3)14 (4.9) 
4 + 469 (49.3)54 (38.6)12 (8.6)5 (3.6) 
4 + 4 + T17 (23.0)29 (39.2)19 (25.7)9 (12.2) 
9 to 10108 (41.2)81 (30.9)42 (16.0)31 (11.8) 

We used Kaplan–Meier analysis with a log-rank test to determine biochemical recurrence-free survival (BFS) among categories. Biochemical recurrence was defined as any postoperative PSA > 0.2 ng/mL. Univariate and multivariate regression models were created to determine predictors of BFS. Only significant variables in univariate analysis were included in the multivariate analysis. Concordance (c) indices were calculated for each model. For the multivariate analysis, the maximum percentage of positive cores (PPC) was assessed as >50 vs ≤50%.

Results

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References

Biopsy Findings

Of the 5205 men with Gleason score ≤6 tumour on biopsy, there was only one with Gleason score 4 and only seven with Gleason score 5; the remaining 99.8% were Gleason score 6. Notably, significant differences in PSA, clinical stage, and number of positive cores were found among the Gleason grade groups at biopsy (Table 1). Patient and prostate cancer characteristics relating to RP findings are depicted in Table 2. The relationship between biopsy Gleason score and RP stage is shown in Table 3. With a median (range) follow-up of 2 (1–8) years, BFS improved incrementally with more well-differentiated tumours (Fig. 1, top). In multivariable analysis, Gleason score was among the strongest preoperative predictors of BFS (Table 4). The 2-year BFS rates for men with biopsy Gleason scores ≤6, 3 + 4, 4 + 3, 8 and 9–10 were 97.1, 90.6, 79.9, 70.9, and 51.5%, respectively (P < 0.001 for trend; P = 0.057 for Gleason score 4 + 3 vs 8 [Fig. 1]).

figure

Figure 1. Kaplan–Meier analysis of Gleason score at biopsy and RP pathological analysis. BFS at 2 and 4 years is shown. The number at risk is shown in brackets after each percentage surviving at a given time interval.

Download figure to PowerPoint

Table 4. Multivariate regression models using preoperative and postoperative variables to predict BFS.
 Multivariate regression
HR (95% CI)P
  1. EPE, extraprostatic extension (pT3a); SVI, seminal vesicle invasion (pT3b); LNI, lymph node involvement (N1).

Preoperative variables  
Family history0.77 (0.54–1.08)0.132
PSA1.06 (1.04–1.07)<0.001
cT2b2.70(1.79–4.06)<0.001
cT2c–cT33.36(1.55–7.31)0.002
Biopsy Gleason score  
3 + 42.19 (1.35–3.56)0.002
4 + 35.38 (3.33–8.68)<0.001
86.92 (3.99–11.98)<0.001
9–1010.27 (5.29–19.92)<0.001
>3 cores0.96 (0.65–1.42)0.834
>50% positive1.99 (1.31–3.00)0.001
Postoperative variables  
Family history0.83 (0.63–1.10)0.195
PSA1.01 (1.00–1.03)0.053
cT2b1.79 (1.28–2.50)0.001
cT2c-cT31.44 (0.82–2.54)0.202
RP Gleason score  
≤6 + Tertiary1.05 (0.42–2.59)0.917
3 + 42.81 (1.53–5.18)0.001
3 + 4 + Tertiary2.88 (1.26–6.61)0.012
4 + 35.66 (3.02–10.59)<0.001
4 + 3 + Tertiary7.14 (3.75–13.61)<0.001
810.31 (5.03–21.13)<0.001
8 + Tertiary7.70 (3.64–16.31)<0.001
9–1012.12 (6.40–22.97)<0.001
EPE3.05 (2.07–4.49)<0.001
SVI6.77 (4.31–10.64)<0.001
LNI6.84 (4.03–11.61)<0.001
Margin1.89 (1.42–2.52)<0.001

Radical Prostatectomy Findings

Of the 3548 men with Gleason score ≤6 tumours as their RP index tumour grade, there was one with Gleason score 4 and there were 44 with Gleason score 5; therefore, 98.7% of RP Gleason score ≤6 tumours were Gleason score 6. Notably, significant differences were found in race, PSA level, clinical stage, number of positive cores at biopsy and the maximum PPC among the Gleason grade groups at RP such that, in general, men with a higher Gleason score at RP were more often African–American, had higher PSA levels, more often had a palpable abnormality on DRE, had more positive cores at biopsy and a greater PPC (Table 2). The relationship of pathological stage to RP Gleason score is shown in Table 3. BFS rates are shown in Fig. 1 and are consistent with the comparison of pathological stage with a higher Gleason score corresponding to worse BFS. The 2-year BFS rates for RP Gleason scores ≤6, ≤6 + T, 3 + 4, 3 + 4 + T, 4 + 3, 4 + 3 + T, 8, 8 + T and 9–10 were 98.8, 97.2, 93.6, 90.3, 85.6, 73.3, 73.7, 60.5 and 58.5%, respectively (P < 0.001 for trend; Fig. 1, bottom). When postoperative variables were assessed in multivariable analysis, RP Gleason grade groups were also among the strongest predictors of BFS (Table 4). The c-index for the complete model was 0.8978. A similar model was created considering only primary Gleason score and ignoring tertiary Gleason patterns (not shown). The c-index for the model excluding tertiary patterns was 0.8970. Based on c-index calculations, considering tertiary Gleason pattern only nominally increases the predictive value of the model and the model excluding tertiary patterns can be considered as predictive as the complete model.

Discussion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References

The Gleason scoring system has proved to be a robust and durable method for the grading of prostate carcinoma. Through several iterations its predictive ability has been improved and, as a consequence, it has become necessarily more complex. The complexity of the newest version of the Gleason grading system can lead to confusion among pathologists, urologists and patients alike. For instance, Gleason score 6 is typically recommended as the lowest grade to be assigned on biopsy material, however, the Gleason scale ranges from 2 to 10, such that patients are unduly concerned when told that they have Gleason score 6 cancer on biopsy, logically but incorrectly assuming that their tumour is in the mid range of aggressiveness. Another consequence of the modified grading system is that there is an expanded definition of Gleason pattern 4 to include a broader range of histological patterns. The original Gleason system restricted Gleason pattern 4 to cases with irregular cribriform architecture and fused glands. In the modified system, almost all cribriform patterns were considered Gleason pattern 4 along with poorly formed and fused glands. Subsequent to the initial publication of the modified system, data have been presented that all cribriform glands should be diagnosed as cribriform pattern 4 [12]. Even in a highly selected set of images thought to be the best candidates for cribriform pattern 3, most experts interpret cribriform patterns as pattern 4 [12]. Furthermore, 73% of the candidates of cribriform pattern 3 were associated with more definitive pattern 4 elsewhere on the needle biopsy specimen. There was poor reproducibility amongst experts as to cribriform pattern 3 vs pattern 4. In a more recent study, specifically addressing the prognosis of cribriform prostate cancer glands, both small and large cribriform glands were equally linked to progression after RP [13].

There are several prognostic consequences of the reclassification of many former Gleason score 6 tumours to Gleason score 7 in the modified system. Gleason score 6 tumours are currently more homogeneous and have a uniformly better prognosis. For example, we have shown that virtually no pure Gleason score 6 tumour is associated with progression after RP, whereas when using the original Gleason system this occasionally occurred [14]. In the present study, 97.1 and 98.8% of patients with pure Gleason 6 cancer at biopsy and RP, respectively, were biochemically free of tumour 2 years after RP. Although other variables must be factored in, such as extraprostatic extension and margin status in the RP and serum PSA level and clinical stage on biopsy, in the modified Gleason system, Gleason score 6 has an excellent prognosis.

The difference between Gleason scores 3 + 4 and 4 + 3 has been well investigated for both post-RP series and studies of biopsies [15-22]. While many of these studies have divergent findings, the majority demonstrate worse pathological stage and biochemical recurrence rates for men with Gleason scores 4 + 3 compared with 3 + 4 [16, 17, 19-21]; however, each of these studies focused on specimens before the reclassification of the Gleason system in 2005 and, furthermore, those published since 2005 are skewed by the inclusion of older samples. In the past, any Gleason pattern 4 tumour was considered to be aggressive, and many authors considered Gleason score 7–10 tumours to be high grade. Using the modified Gleason system, the present study showed that a Gleason score 3 + 4 = 7 tumour has a very favourable prognosis with estimated 2-year BFS of 90.6 and 93.6% for biopsy and RP, respectively. These results warrant the separation of Gleason score 7 into two prognostic groups. Further evidence against combining all Gleason score 7 tumours into one category is that, in the present study, Gleason score 4 + 3 = 7 carcinomas behaved more similarly to tumours with Gleason score 8 than they did to those with Gleason score 3 + 4 = 7.

With Gleason score 8 tumours, the prognosis worsens considerably, yet not to the level of Gleason score 9–10. Within the literature, Gleason scores 8–10 are typically considered as one grade category. In large part, this results from many RP series having relatively few patients with Gleason score 9–10; for the purposes of having enough cases for meaningful statistical analysis they are combined with the more numerous cases of Gleason score 8. Although Gleason score 9–10 tumours are not rare, most of the men with this tumour grade have advanced clinical disease such that they are not candidates for RP. Given the almost ubiquitous lumping together of Gleason scores 8, 9 and10 in the literature, including within commonly used predictive tables and nomograms, it is not surprising that some urologists consider Gleason score 8 as being prognostically the same as Gleason score 9–10. As the present study clearly shows, however, Gleason score 9–10 tumours have almost twice the risk of progression compared with Gleason score 8. At biopsy and RP, 70.9 and 73.7%, respectively, of men with Gleason score 8 tumours are free of biochemical recurrence at 2 years. There is a precipitous drop in predicted cure for men with Gleason score 9 and10 cancer at biopsy and RP, where only 66.7 and 58.5%, respectively, are free of biochemical recurrence at 2 years. Unfortunately, for the reasons stated above, predictive tables and nomograms overestimate the cure rate for Gleason score 9–10 tumours, by combining these cases with the more common better prognosis Gleason score 8 lesions. There are also numerous studies in the radiation literature as to the worse prognosis for men with Gleason score 9–10 tumours as opposed to Gleason score 8 [23].

In the present study and in previous studies, the presence of a tertiary higher grade component was associated with an increased risk of biochemical recurrence, typically raising the risk of recurrence to an intermediate level between those of cancers without a tertiary component in the same Gleason score category and cancers in the next higher Gleason score category. For example, Gleason score 3 + 3 = 6 with tertiary pattern 4 has a prognosis that is in between Gleason score 3 + 3 = 6 without tertiary pattern 4 and Gleason score 3 + 4 = 7. Gleason score 3 + 4 = 7 with tertiary pattern 5 has a prognosis intermediate between Gleason score 3 + 4 = 7 without a tertiary pattern 5 and Gleason score 4 + 3 = 7. The one exception is RP Gleason score 4 + 3 = 7 with tertiary pattern 5, which has progression rates more similar to Gleason score 8 [24, 25]. Other studies have found a different prognostic effect of tertiary higher grade patterns. For example, Turker et al. [25] demonstrated that Gleason score 6 tumours with tertiary higher grade patterns behaved in a similar way to Gleason score 3 + 4 = 7 tumours. They also reported that Gleason score 3 + 4 plus tertiary pattern 5, Gleason score 4 + 3 plus tertiary pattern 5, and Gleason score 8–10 all had similar prognoses [26].

The present study failed to show that adding the tertiary component enhanced the predictive value in multivariable analysis factoring in preoperative serum PSA levels and pathological stage, margins and Gleason grade. Whittemore et al. [27] also found that the prognostic significance of tertiary pattern 5 in Gleason score 7 tumours dropped out in multivariable analysis. In summary, tertiary Gleason patterns are typically associated with higher pathological stage and biochemical recurrence than cancers with the same Gleason score without tertiary patterns. The relative increase in risk of recurrence associated with tertiary patterns differs between studies. It is currently recommended that tertiary grade patterns are noted in the pathology report to accurately reflect the grade, although it is questionable whether tertiary grade patterns add prognostic information to routinely reported variables

It could be argued that the numbering system of the Gleason grading system should be abandoned and replaced with a new grading system of I–V, reflecting Gleason scores ≤6; 3 + 4 = 7; 4 + 3 = 7; 8; and 9–10, respectively. By doing so, we would avoid the current grading system that to all intents and purposes begins with 6. The Gleason system, however, is deeply entrenched in the history and literature of prostate carcinoma – a quick Medline search of ‘Gleason score’, ‘Gleason sum’ or ‘Gleason grade’ reveals 5957 articles. A reassignment of the Gleason numbers to a simple I–V grading system would create mass confusion for patient care and when comparing data with older studies using the conventional Gleason grading numbering, which goes from 2 to 10. The issue remains of how to best manage and discuss the grading of prostate carcinoma. On the one hand, we have demonstrated that an accurate grouping of Gleason scores can be accomplished with five prognostic grade groups, as opposed to the individual nine Gleason scores. On the other hand, oversimplification of Gleason grade classification, such as by combining Gleason scores 8–10 or categorizing patients into low-, intermediate- and high-risk categories based on Gleason scores <7, = 7 and >7 loses critical prognostic information [7]. We recommend reporting whenever possible in analyses within the literature the five prognostic grade groups that we have demonstrated to be prognostically distinct. If it is not feasible to do so because of insufficient numbers of patients within each prognostic grade group, this limitation should be acknowledged.

There are several limitations to the present study, the first being the short-term follow-up with regard to BFS and lack of cancer-specific survival data. Since the modified Gleason system was only implemented in 2005, the data are necessarily constricted, but the fact that the data are internally consistent with incrementally worsening prognosis for each prognostic grade group, as would be expected, makes it unlikely that the results would change significantly with longer follow-up. The Kaplan–Meier analysis and curves take into account the length of follow-up, and weight greater prognostic information for those patients with longer follow-up, but studies with longer follow-up using the modified Gleason system are necessary to verify our results. Another potential weakness is that we did not have data on all cases for the number of cores sampled since the majority of cases were biopsied in outside institutions. Consequently, we report the number of positive cores as opposed to the fraction of positive cores (number of positive cores/total cores). In a previous study of >3000 needle biopsy specimens analysed at our institution, between 10 and 15 cores were sampled in 67.5% of the cases, and the remaining 32.5% were evenly distributed between <10 and >15 cores with only one patient with a sextant biopsy. Given the relatively narrow range of number of cores sampled, we have found in our data virtually the same statistical results whether the number or fraction of positive cores is used [28].

In summary, the 2005 ISUP modifications to the Gleason grading system for prostate carcinoma accurately categorize patients by pathological findings and short-term biochemical outcomes. While retaining the essence of the Gleason system, there is a need for a change in its reporting to more closely reflect tumour behaviour. In reporting grades on biopsy and RP, we propose recording the Gleason score, and including prognostic grade groups (Table 5). One would still report a case, for example, as ‘Gleason score 9’ or as ‘Gleason score 10’, (rather than as ‘Gleason score 9–10’) along with the prognostic grade group V. Patients will, for example, be reassured that when diagnosed with a Gleason score 6 that their prognostic grade group is I out of V, not Gleason score 6 out of 10. The same would apply for a Gleason score 3 + 4 = 7 tumour where both the prognostic grade group (II) in line with their tumour's relatively less aggressive behaviour. At the other end of the grade spectrum, men with Gleason score 9–10 tumours will more accurately be considered to have more aggressive tumours than those with Gleason score 8, and this can be factored into their management.

Table 5. Reporting of Gleason score Prognostic Grade Groups
The overall Gleason score for this case is based on the core with the highest Gleason score. Gleason scores can be grouped and range from Prognostic Grade Group I (most favorable) to Prognostic Grade Group V (least favorable).
Gleason score ≤ 6:Prognostic Grade Group I
Gleason score 3 + 4 = 7:Prognostic Grade Group II
Gleason score 4 + 3 = 7:Prognostic Grade Group III
Gleason score 8:Prognostic Grade Group IV
Gleason score 9–10:Prognostic Grade Group V

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Conflict of Interest
  8. References
  • 1
    Mellinger GT, Gleason D, Bailar J 3rd. The histology and prognosis of prostatic cancer. J Urol 1967; 97: 331337
  • 2
    Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 5864
  • 3
    Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 12281242
  • 4
    Billis A, Guimaraes MS, Freitas LL et al. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008; 180: 548552; discussion 552–3
  • 5
    Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006; 449: 622627
  • 6
    Ozok HU, Sagnak L, Tuygun C et al. Will the modification of the Gleason grading system affect the urology practice? Int J Surg Pathol 2010; 18: 248254
  • 7
    Tsivian M, Sun L, Mouraviev V et al. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009; 74: 10901093
  • 8
    Uemura H, Hoshino K, Sasaki T et al. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int 2009; 103: 11901194
  • 9
    Berney DM, Fisher G, Kattan MW et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007; 100: 12401244
  • 10
    Trock BJ, Guo CC, Gonzalgo ML et al. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol 2009; 182: 13641370
  • 11
    Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 35823593
  • 12
    Latour M, Amin MB, Billis A et al. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol 2008; 32: 15321539
  • 13
    Iczkowski KA, Torkko KC, Kotnis GR et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 2011; 136: 98107
  • 14
    Miyamoto H, Hernandez DJ, Epstein JI. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Hum Pathol 2009; 40: 16931698
  • 15
    Alenda O, Ploussard G, Mouracade P et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol 2010; 29: 671676
  • 16
    Burdick MJ, Reddy CA, Ulchaker J et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 14391445
  • 17
    Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823827
  • 18
    Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001; 25: 657660
  • 19
    Kang DE, Fitzsimons NJ, Presti JC Jr et al. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 2007; 70: 277282
  • 20
    Koontz BF, Tsivian M, Mouraviev V et al. Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys 2012; 82: 200203
  • 21
    Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002; 167: 24402442
  • 22
    Rasiah KK, Stricker PD, Haynes AM et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003; 98: 25602565
  • 23
    Sabolch A, Feng FY, Daignault-Newton S et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011; 81: e351360
  • 24
    Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000; 24: 563569
  • 25
    Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JI. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004; 28: 394398
  • 26
    Turker P, Bas E, Bozkurt S et al. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival. Urol Oncol 2011; [Epub ahead of print]
  • 27
    Whittemore DE, Hick EJ, Carter MR et al. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008; 179: 516522; discussion 522
  • 28
    Amin A, Partin A, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol 2011; 186: 12861290